Literature DB >> 33542909

Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis.

Changzhou Cai1, Xin Song1, Xueyang Chen1, Weihua Zhou1,2, Qi Jin1, Shenghui Chen1, Feng Ji1.   

Abstract

Background and Aims: Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) have become common chronic liver diseases. Recent evidence has shown the value of transient elastography (TE) in the context of ALD/NAFLD. The aim of this study is to investigate the accuracy of TE for diagnosing steatosis and fibrosis in ALD/NAFLD patients.
Methods: We retrieved relevant English studies from the databases of PubMed, Embase, the Web of Science, and the Cochrane Library through March 31st 2019. We included studies regarding the diagnosis or staging of steatosis or fibrosis by using controlled attenuation parameter (CAP) or liver stiffness measurement (LSM) measured by TE in patients with ALD or NAFLD. The reference standard of all included studies was liver biopsy. A random-effects model was applied. Statistical analyses were performed using STATA.
Results: A total of 62 articles were included and analyzed in our meta-analysis. In patients with ALD/NAFLD, the pooled results revealed that the sensitivity and specificity of CAP were 0.84, 0.83, and 0.78 and 0.83, 0.71, and 0.62 for steatosis grades ≥ S1, ≥S2, and =S3, respectively. The sensitivity and specificity of LSM for identifying fibrosis grades ≥ F1, ≥F2, ≥F3, and =F4 were 0.77, 0.77, 0.83, and 0.91 and 0.80, 0.82, 0.84, and 0.86, respectively.
Conclusion: In patients with ALD/NAFLD, CAP was feasible for identifying and screening steatosis, and LSM was accurate for diagnosing fibrosis, especially severe fibrosis and cirrhosis.
Copyright © 2021 Changzhou Cai et al.

Entities:  

Year:  2021        PMID: 33542909      PMCID: PMC7840258          DOI: 10.1155/2021/8859338

Source DB:  PubMed          Journal:  Can J Gastroenterol Hepatol        ISSN: 2291-2789


  25 in total

1.  Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Mohammad S Siddiqui; Raj Vuppalanchi; Mark L Van Natta; Erin Hallinan; Kris V Kowdley; Manal Abdelmalek; Brent A Neuschwander-Tetri; Rohit Loomba; Srinivasan Dasarathy; Danielle Brandman; Edward Doo; James A Tonascia; David E Kleiner; Naga Chalasani; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-26       Impact factor: 11.382

2.  Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.

Authors:  Victor de Lédinghen; Grace Lai-Hung Wong; Julien Vergniol; Henry Lik-Yuen Chan; Jean-Baptiste Hiriart; Anthony Wing-Hung Chan; Faiza Chermak; Paul Cheung-Lung Choi; Juliette Foucher; Carmen Ka-Man Chan; Wassil Merrouche; Angel Mei-Ling Chim; Brigitte Le Bail; Vincent Wai-Sun Wong
Journal:  J Gastroenterol Hepatol       Date:  2016-04       Impact factor: 4.029

3.  MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis.

Authors:  Jurgen Henk Runge; Loek Pieter Smits; Joanne Verheij; Annekatrien Depla; Sjoerd Douwe Kuiken; Bert Cornelis Baak; Aart Johannes Nederveen; Ulrich Beuers; Jaap Stoker
Journal:  Radiology       Date:  2017-09-15       Impact factor: 11.105

4.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

Authors:  Leon A Adams; James F Lymp; Jenny St Sauver; Schuyler O Sanderson; Keith D Lindor; Ariel Feldstein; Paul Angulo
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

5.  Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis.

Authors:  Sebastian Mueller; Gunda Millonig; Lucie Sarovska; Stefanie Friedrich; Frank M Reimann; Maria Pritsch; Silke Eisele; Felix Stickel; Thomas Longerich; Peter Schirmacher; Helmut Karl Seitz
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

6.  Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease.

Authors:  Vincent Wai-Sun Wong; Marie Irles; Grace Lai-Hung Wong; Sarah Shili; Anthony Wing-Hung Chan; Wassil Merrouche; Sally She-Ting Shu; Juliette Foucher; Brigitte Le Bail; Wah Kheong Chan; Henry Lik-Yuen Chan; Victor de Ledinghen
Journal:  Gut       Date:  2019-01-18       Impact factor: 23.059

Review 7.  Non-invasive diagnosis and biomarkers in alcohol-related liver disease.

Authors:  Christophe Moreno; Sebastian Mueller; Gyongyi Szabo
Journal:  J Hepatol       Date:  2019-02       Impact factor: 25.083

8.  Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?

Authors:  Manoj Kumar; Archana Rastogi; Tarandeep Singh; Chhagan Behari; Ekta Gupta; Hitendra Garg; Ramesh Kumar; Vikram Bhatia; Shiv K Sarin
Journal:  J Gastroenterol Hepatol       Date:  2013-07       Impact factor: 4.029

9.  Controlled attenuation parameter for diagnosing steatosis in bariatric surgery candidates with suspected nonalcoholic fatty liver disease.

Authors:  Sylvie Naveau; Cosmin S Voican; Amandine Lebrun; Martin Gaillard; Karima Lamouri; Micheline Njiké-Nakseu; Rodi Courie; Hadrien Tranchart; Axel Balian; Sophie Prévot; Ibrahim Dagher; Gabriel Perlemuter
Journal:  Eur J Gastroenterol Hepatol       Date:  2017-09       Impact factor: 2.566

10.  Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.

Authors:  Maja Thiele; Vanessa Rausch; Gabriele Fluhr; Maria Kjærgaard; Felix Piecha; Johannes Mueller; Beate Katharina Straub; Monica Lupșor-Platon; Victor De-Ledinghen; Helmut Karl Seitz; Sönke Detlefsen; Bjørn Madsen; Aleksander Krag; Sebastian Mueller
Journal:  J Hepatol       Date:  2018-01-16       Impact factor: 25.083

View more
  5 in total

1.  Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Yu-Tian Cao; Liu-Lan Xiang; Fang Qi; Yu-Juan Zhang; Yi Chen; Xi-Qiao Zhou
Journal:  EClinicalMedicine       Date:  2022-07-10

Review 2.  Liver Transplant Imaging prior to and during the COVID-19 Pandemic.

Authors:  Maria Irene Bellini; Daniele Fresilli; Augusto Lauro; Gianluca Mennini; Massimo Rossi; Carlo Catalano; Vito D'Andrea; Vito Cantisani
Journal:  Biomed Res Int       Date:  2022-01-12       Impact factor: 3.411

Review 3.  Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches.

Authors:  Eirini Martinou; Marinos Pericleous; Irena Stefanova; Vasha Kaur; Angeliki M Angelidi
Journal:  Diagnostics (Basel)       Date:  2022-02-04

Review 4.  Ultrasound Elastography-Cornerstone of Non-Invasive Metabolic Dysfunction-Associated Fatty Liver Disease Assessment.

Authors:  Andrej Hari
Journal:  Medicina (Kaunas)       Date:  2021-05-21       Impact factor: 2.430

5.  High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort.

Authors:  Elba Llop; Paula Iruzubieta; Christie Perelló; Carlos Fernández Carrillo; Joaquín Cabezas; María Desamparados Escudero; Marta González; Marta Hernández Conde; Laura Puchades; María Teresa Arias-Loste; Miguel Ángel Serra; Javier Crespo; José Luis Calleja
Journal:  United European Gastroenterol J       Date:  2021-06-02       Impact factor: 4.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.